Imukin (Recombinant Human Interferon Gamma 1b)

The molecule binds to the interferon‑gamma receptor on immune cells, triggering the JAK‑STAT pathway. Activated STAT1 translocates to the nucleus, inducing genes that increase antigen presentation, macrophage microbicidal activity, and Th1‑type cytokine production, while also promoting osteoclast differentiation, thereby supporting host defense and bone turnover.

The dosage of Imukin is individualized by the prescribing physician based on the patient’s age, weight, disease severity, and clinical response. The prescriber determines the appropriate subcutaneous injection volume and frequency, and adjustments are made according to therapeutic monitoring and tolerability.

The safety of Imukin in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus. Data on excretion in human milk are lacking, so breastfeeding is generally not recommended unless the benefit to the mother outweighs possible risks to the infant.

To request Imukin, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and required import documentation.

Compared with other immunostimulants such as recombinant interleukin‑2 or granulocyte‑macrophage colony‑stimulating factor, Imukin specifically activates the interferon‑gamma pathway, leading to pronounced macrophage activation and Th1 polarization. Its clinical use is limited to the two rare indications, whereas other agents may have broader oncology or transplant applications but different safety profiles.

Imukin must be stored in a refrigerator at 2 °C to 8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. If temperature excursions occur, consult the supplier before use.

Imukin is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdomen, thigh, or upper arm using a sterile needle and syringe. Administration should be performed by a healthcare professional or trained caregiver following aseptic technique and the prescriber’s dosing schedule.

Serious adverse events include hematologic abnormalities such as anemia, leukopenia, or thrombocytopenia; hepatic injury manifested by elevated liver enzymes or hepatitis; autoimmune reactions like lupus‑like syndrome; and severe hypersensitivity reactions including anaphylaxis. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Imukin is contraindicated in patients with known hypersensitivity to interferon‑gamma or any excipients in the formulation. It should be used with caution, or avoided, in individuals with active autoimmune disease, uncontrolled hepatic impairment, or those receiving live vaccines, as the drug may exacerbate these conditions.